Search
Feed aggregator
Rapport Therapeutics Snags $100M for Precision Approach to Neurological Diseases
Rapport Therapeutics Snags $100M for Precision Approach to Neurological Diseases 3/7/2023
Moderna Eyes Accelerated Approval for mRNA Cancer Vaccine
Moderna Eyes Accelerated Approval for mRNA Cancer Vaccine 3/7/2023
Lilly-Backed Volastra Enters Clinic with Amgen’s KIF18A Inhibitor
Lilly-Backed Volastra Enters Clinic with Amgen’s KIF18A Inhibitor 3/7/2023
Merck Preps Potential First Oral PCSK9 Inhibitor for Phase III
Merck Preps Potential First Oral PCSK9 Inhibitor for Phase III 3/7/2023
Small Study of BridgeBio's Dwarfism Drug Indicates Advantage over BioMarin
Small Study of BridgeBio's Dwarfism Drug Indicates Advantage over BioMarin 3/7/2023
AI Therapeutics Posts First Clinical Data for New ALS Mechanism
AI Therapeutics Posts First Clinical Data for New ALS Mechanism 4/6/2023
Hedge Fund Wages Proxy Battle with Exelixis Over R&D
Hedge Fund Wages Proxy Battle with Exelixis Over R&D 4/6/2023
NLRB Rules Severance Agreements with Nondisclosure Clauses are Unlawful
NLRB Rules Severance Agreements with Nondisclosure Clauses are Unlawful 4/6/2023
Pfizer Publishes Phase III RSV Data Ahead of May Decision
Pfizer Publishes Phase III RSV Data Ahead of May Decision 4/6/2023
How the IRA Will Affect Drug Development
How the IRA Will Affect Drug Development 4/6/2023
FDA Sets July Decision Date for Full Approval of Leqembi
FDA Sets July Decision Date for Full Approval of Leqembi 3/6/2023
Voyager Rolls on as Novartis Selects Two of Three CNS Targets
Voyager Rolls on as Novartis Selects Two of Three CNS Targets 3/6/2023
Full Results from Esperion's Cholesterol Drug Fail to Impress Investors
Full Results from Esperion's Cholesterol Drug Fail to Impress Investors 3/6/2023
Incyte Abandons Phase III Trial for Myelofibrosis Treatment
Incyte Abandons Phase III Trial for Myelofibrosis Treatment 3/6/2023
How to Nail Virtual Interviews & Networking Events
How to Nail Virtual Interviews & Networking Events 3/6/2023
FDA Action Alert: Roche and Acadia
FDA Action Alert: Roche and Acadia 3/6/2023
Bayer launches unit to develop new precision health consumer products
The Consumer Health Division of Bayer has launched a business unit focused on developing new Precision Health products across its range of everyday health categories. Bayer will prioritize developing products that enable people to take greater control of their own personal health through digital solutions that facilitate more informed choices based on personal insights and novel delivery mechanisms.
AbbVie’s Rinvoq Maintains Durability in Phase II Lupus Study
AbbVie’s Rinvoq Maintains Durability in Phase II Lupus Study 5/31/2023
FDA Puts Clinical Hold on PepGen’s DM1 Early-Stage Trial
FDA Puts Clinical Hold on PepGen’s DM1 Early-Stage Trial 5/31/2023
Sanofi Rebounds in MS with Mid-Stage Data for Anti-CD40L Antibody
Sanofi Rebounds in MS with Mid-Stage Data for Anti-CD40L Antibody 5/31/2023
World Pharma News
- Bayer launches unit to develop new precision health consumer products
- Researchers use ‘natural’ system to identify proteins most useful for developing an effective HIV vaccine
- New blood biomarker can predict if cognitively healthy elderly will develop Alzheimer's disease
- Large study provides scientists with deeper insight into long COVID symptoms
- Pfizer's PAXLOVID™ receives FDA approval for adult patients at high risk of progression to severe COVID-19